Apexigen, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$6M
Investors
13
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Apexigen, Inc. is an entity organized in Delaware that filed a Form D with the SEC on September 5, 2023. The offering claims Securities Exchange Act of 1934. Apexigen, Inc. reported $5,587,982 sold from 13 investors as of the Form D filed September 5, 2023. The Form D names Brookline Capital Markets, a division of Arcadia Securities, LLC (CRD 44656), associated with None as the recipient of sales compensation soliciting in all states. The issuer's address of record is 900 Industrial Road, Suite C, San Carlos, CA 94070.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Sep 5, 2023
Critical / warning
0 / 1
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
closed
Latest event Exchange act deregistration · Sep 5, 2023
SEC.govFund family Part of the Apexigen family: 2 vehicles across 0 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 filing event with values and deltas, latest 2023-09-05, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Xiaodong Yang
Executive Officer, Director · San Carlos, CA
President and CEO
Francis Sarena
Executive Officer · San Carlos, CA
Chief Operating Officer
William Duke, Jr.
Executive Officer · San Carlos, CA
Chief Financial Officer
Frank Hsu
Executive Officer · San Carlos, CA
Chief Medical Officer
Amy Wong
Executive Officer · San Carlos, CA
Senior VP, Finance and Operations
Meenu Karson
Director · San Carlos, CA
Chair of the Board
Dan Zabrowski
Director · San Carlos, CA
Scott Smith
Director · San Carlos, CA
Herb Cross
Director · San Carlos, CA
Jakob Dupont
Director · San Carlos, CA
Gordon Ringold
Director · San Carlos, CA
Samuel Wertheimer
Director · San Carlos, CA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Brookline Capital Markets, a division of Arcadia Securities, LLCCRD 44656 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states and outside the United States
Questions About Apexigen, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Apexigen, Inc.?
Apexigen, Inc. is an issuer that filed a Form D with the SEC on September 5, 2023. The filing claims Securities Exchange Act of 1934.
Is Apexigen, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Apexigen, Inc. filed a Form D with the SEC on September 5, 2023 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $5,587,982 sold to 13 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Apexigen, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Apexigen, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Apexigen, Inc. raised?
Apexigen, Inc. reported $5,587,982 sold from 13 investors as of the Form D filed September 5, 2023.
Who is selling Apexigen, Inc. and how are they paid?
The Form D names Brookline Capital Markets, a division of Arcadia Securities, LLC (CRD 44656), associated with None as the recipient of sales compensation soliciting in all states.
Who is behind Apexigen, Inc.?
The Form D lists 12 related persons: Xiaodong Yang, executive officer, director (President and CEO); Francis Sarena, executive officer (Chief Operating Officer); William Duke, Jr., executive officer (Chief Financial Officer); Frank Hsu, executive officer (Chief Medical Officer); Amy Wong, executive officer (Senior VP, Finance and Operations); Meenu Karson, director (Chair of the Board); Dan Zabrowski, director; Scott Smith, director, and 4 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Apexigen, Inc. located?
The issuer's address on its SEC filings is 900 Industrial Road, Suite C, San Carlos, CA 94070. Its phone number of record is 650.931.6236. It is organized under the laws of Delaware.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.